Jeffrey A Zonder

Summary

Affiliation: Wayne State University
Country: USA

Publications

  1. ncbi request reprint Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylate
    Jeffrey A Zonder
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Harper Hospital, 4 Brush South, 3990 John R, Detroit, MI 48201, USA
    Curr Hematol Rep 2:57-64. 2003
  2. doi request reprint A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
    Jeffrey A Zonder
    Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R St, Detroit, MI 48201, USA
    Blood 120:552-9. 2012
  3. ncbi request reprint Chronic lymphocytic leukemia presenting in association with aplastic anemia
    Jeffrey A Zonder
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Am J Hematol 71:323-7. 2002
  4. ncbi request reprint The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment
    Jeffrey A Zonder
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 9:2092-7. 2003
  5. doi request reprint Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate
    Jeffrey A Zonder
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R, Detroit, MI 48201, USA
    Curr Hematol Malig Rep 1:141-51. 2006
  6. pmc Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)
    Jeffrey A Zonder
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Blood 116:5838-41. 2010
  7. pmc Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
    Suzanne Lentzsch
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA, USA
    Blood 119:4608-13. 2012
  8. pmc Clinical development of novel proteasome inhibitors for cancer treatment
    Huanjie Yang
    The Prevention Program, Barbara Ann Karmanos Cancer Institute, and the Department of Pathology, School of Medicine, Wayne State University, 540 1 HWCRC, 4100 John R Road, Detroit, Michigan 48201, USA
    Expert Opin Investig Drugs 18:957-71. 2009

Detail Information

Publications8

  1. ncbi request reprint Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylate
    Jeffrey A Zonder
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Harper Hospital, 4 Brush South, 3990 John R, Detroit, MI 48201, USA
    Curr Hematol Rep 2:57-64. 2003
    ..The feasibility of combining imatinib with other agents also needs to be examined, as does the utility of molecular monitoring of response. Finally, developing methods to overcome resistance to imatinib is a looming challenge...
  2. doi request reprint A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
    Jeffrey A Zonder
    Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R St, Detroit, MI 48201, USA
    Blood 120:552-9. 2012
    ..5%) had stable disease. In summary, elotuzumab was generally well tolerated in this population, justifying further exploration of this agent in combination regimens...
  3. ncbi request reprint Chronic lymphocytic leukemia presenting in association with aplastic anemia
    Jeffrey A Zonder
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Am J Hematol 71:323-7. 2002
    ..Possible humoral and cellular autoimmune mechanisms are examined as possible causes of marrow aplasia in this setting...
  4. ncbi request reprint The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment
    Jeffrey A Zonder
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 9:2092-7. 2003
    ..Some patients with chronic-phase or accelerated-phase CML either relapse after an initial response or are refractory to imatinib, prompting us to evaluate the efficacy of dose increase in such patients...
  5. doi request reprint Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate
    Jeffrey A Zonder
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R, Detroit, MI 48201, USA
    Curr Hematol Malig Rep 1:141-51. 2006
    ..Finally, recent data on new tyrosine kinase inhibitors capable of overcoming primary or acquired resistance to imatinib are reviewed...
  6. pmc Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)
    Jeffrey A Zonder
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Blood 116:5838-41. 2010
    ..001; thromboembolic events despite aspirin prophylaxis: 23.5% [initial LEN-DEX or crossover] vs 5%; P < .001). This trial was registered at www.clinicaltrials.gov as #NCT00064038...
  7. pmc Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
    Suzanne Lentzsch
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA, USA
    Blood 119:4608-13. 2012
    ..This first phase 1/2 trial testing bendamustine, lenalidomide, and dexamethasone as treatment of relapsed refractory MM was feasible and highly active. This study is registered at www.clinicaltrials.gov as #NCT01042704...
  8. pmc Clinical development of novel proteasome inhibitors for cancer treatment
    Huanjie Yang
    The Prevention Program, Barbara Ann Karmanos Cancer Institute, and the Department of Pathology, School of Medicine, Wayne State University, 540 1 HWCRC, 4100 John R Road, Detroit, Michigan 48201, USA
    Expert Opin Investig Drugs 18:957-71. 2009
    ..Emerging evidence demonstrates that targeting the tumor proteasome is a promising strategy for cancer therapy...